Patents Assigned to AGEX THERAPEUTICS, INC.
  • Publication number: 20210338822
    Abstract: The invention provides improved methods, compositions, uses and kits relating to exosomes isolated from cells and therapeutic compositions and methods of using those exosomes. In one embodiment, the exosomes are loaded with one or more molecules to provide a desired therapeutic effect.
    Type: Application
    Filed: January 22, 2021
    Publication date: November 4, 2021
    Applicant: AgeX Therapeutics, Inc.
    Inventors: Dana LaRocca, Jieun Lee, Hal Sternberg
  • Publication number: 20210180013
    Abstract: Aspects of the present invention include compositions and methods for discovering novel compositions and applying said compositions in treating medical conditions including aging, degenerative disease, wound treatment, and cancer through the modulation of molecular pathways regulating regeneration and senolysis by means of altering the embryonic-fetal and prenatal/postnatal transitional states of mammalian cells.
    Type: Application
    Filed: April 23, 2019
    Publication date: June 17, 2021
    Applicant: AgeX Therapeutics, Inc.
    Inventors: Michael D. West, Hal Stemberg
  • Patent number: 10961531
    Abstract: Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: March 30, 2021
    Assignee: AgeX Therapeutics, Inc.
    Inventors: Michael D. West, Karen Chapman, Hal Sternberg
  • Publication number: 20200309776
    Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Applicants: AgeX Therapeutics, Inc., AgeX Therapeutics, Inc.
    Inventor: Basil M. HANTASH
  • Publication number: 20200306296
    Abstract: Exosomes are generated from host embryonal carcinoma or embryonic progenitor cell lines and used for induced tissue regeneration. These inventive compositions and methods provide for induced tissue regeneration in aged or diseased mammalian tissues in vivo without the use of transgenically-expressed genes. Cells are reprogrammed to a prenatal, indeed a pre-fetal state, as indicated by for example in the case of many stromal cell types, by a decrease in the markers ADIRF and COX7A1.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Applicant: AgeX Therapeutics, Inc.
    Inventors: Michael West, Dana Larocca, Jieun Lee
  • Publication number: 20200225213
    Abstract: A method of screening a composition for cardiotoxicity comprising contacting the composition with cardiomyocytes that have increased fatty acid oxidation and/or diminished glucose oxidation. The cardiomyocytes are preferably prepared by overexpression of COX7A1. The cardiomyocytes are preferably provided in a micropatterned co-culture to provide a mature functional hPSC-CM cardiotoxicity model.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 16, 2020
    Applicant: AgeX Therapeutics, Inc.
    Inventors: Michael D. West, Jeffrey Janus
  • Patent number: 10502738
    Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 10, 2019
    Assignee: AGEX THERAPEUTICS, INC.
    Inventor: Basil M. Hantash